Skip to main content

Advertisement

SpringerLink
Log in

LINC00941: a novel player involved in the progression of human cancers

  • Review Article
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

LINC00941, also known as lncRNA-MUF, is an intergenic non-coding RNA located on chromosome 12p11.21. It actively participates in a complex competing endogenous RNA network, regulating the expression of microRNA and its downstream proteins. Through transcriptional and post-transcriptional regulation, LINC00941 plays a vital role in multiple signaling pathways, influencing cell behaviors such as tumor cell proliferation, epithelial–mesenchymal transition, migration, and invasion. Noteworthy is its consistently high expression in various tumor types, closely correlating with clinicopathological features and cancer prognoses. Elevated LINC00941 levels are associated with adverse clinical outcomes, including increased tumor size, extensive lymphatic metastasis, and distant metastasis, leading to poorer survival rates across different cancers. Additionally, LINC00941 and its associated genes are linked to various targeted drugs available in the market. In this comprehensive review, we systematically summarize existing studies, detailing LINC00941's differential expression, clinicopathological and prognostic implications, regulatory mechanisms, and associated therapeutic drugs. Our analysis includes relevant charts and incorporates bioinformatics analyses to verify LINC00941's differential expression in pan-cancer and explore potential transcriptional regulation patterns of downstream targets. This work not only establishes a robust data foundation but also guides future research directions. Given its potential as a significant cancer biomarker and therapeutic target, further investigation into LINC00941's differential expression and regulatory mechanisms is essential.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

Not applicable.

Abbreviations

ACC:

Adrenocortical carcinoma

ALL:

Acute lymphoblastic leukemia

AML:

Acute myeloid leukemia

BLCA:

Bladder urothelial carcinoma

BRCA:

Breast invasive carcinoma

ceRNA:

Competing endogenous RNA

CESC:

Cervical esophageal squamous cell carcinoma

CHOL:

Cholangiocarcinoma

COAD:

Colon adenocarcinoma

CRC:

Colorectal cancer

DFS:

Disease-free survival

EMT:

Epithelial–mesenchymal transition

ESCA:

Esophageal carcinoma

ESCC:

Esophageal squamous cell carcinoma

FAK:

Focal adhesion kinase

GBM:

Glioblastoma multiforme

GC:

Gastric cancer

HCC:

Hepatocellular carcinoma

HNSC:

Head and neck squamous cell carcinoma

KICH:

Kidney chromophobe

KIRC:

Kidney renal clear cell carcinoma

KIRP:

Kidney papillary cell carcinoma

LATS1/2:

Large tumor suppressor 1/2

LC:

Laryngocarcinoma

LGG:

Lower grade glioma

LIHC:

Liver hepatocellular carcinoma

LncRNA:

Long non-coding RNA

LUAD:

Lung adenocarcinoma

LUSC:

Lung squamous cell carcinoma

miRNA:

MicroRNA

miRNA-RISC:

MiRNA-containing RNA-induced silencing complex

MREs:

MicroRNA response elements

MST1/2:

Mammalian sterile20-like kinase 1/2

NBL:

Neuroblastoma

NSCLC:

Non-small cell lung cancerr

OV:

Ovarian cancer

OS:

Overall survival

OSCC:

Oral squamous cell carcinoma

PAAD:

Pancreatic adenocarcinoma

PC:

Pancreatic cancer

PCPG:

Pheochromocytoma and paraganglioma cancer

PDAC:

Pancreatic ductal adenocarcinoma

PP2A:

Protein phosphatase 2A

PRAD:

Prostate adenocarcinoma

PTC:

Primes papillary thyroid cancer

READ:

Rectum adenocarcinoma

SARC:

Sarcoma

SKCM:

Skin cutaneous melanoma

SPP:

Signaling pathways project

STAD:

Stomach adenocarcinoma

TGCT:

Testicular germ cell tumors

TGF- β:

Transforming growth factor-β

THCA:

Thyroid carcinoma

THYM:

Thymoma

TNM:

Tumor node metastasis

TSS:

Transcription start site

UCEC:

Endometrioid cancer

UCS:

Uterine carcinosarcoma

UCSC Genome Browser:

http://genome.ucsc.edu/

CADDIE database:

https://exbio.wzw.tum.de/caddie/

ChIP-Atlas:

https://chip-atlas.org/

JASPAR 2022 database:

https://jaspar.genereg.net/

SPP database:

http://signalingpathways.org/index.jsf

TCGA database:

https://portal.gdc.cancer.gov/

References

  1. Yan H, Bu P. Non-coding RNA in cancer. Essays Biochem. 2021;65:625–39.

    PubMed  PubMed Central  CAS  Google Scholar 

  2. Li C, Ni YQ, Xu H, et al. Roles and mechanisms of exosomal non-coding RNAs in human health and diseases. Signal Transduct Target Ther. 2021;6:383.

    PubMed  PubMed Central  CAS  Google Scholar 

  3. Ai Y, Wu S, Zou C, Wei H. LINC00941 promotes oral squamous cell carcinoma progression via activating CAPRIN2 and canonical WNT/beta-catenin signaling pathway. J Cell Mol Med. 2020;24:10512–24.

    PubMed  PubMed Central  CAS  Google Scholar 

  4. Zhang Q, Shen J, Wu Y, Ruan W, Zhu F, Duan S. LINC00520: A Potential Diagnostic and Prognostic Biomarker in Cancer. Front Immunol. 2022;13:845418.

    PubMed  PubMed Central  CAS  Google Scholar 

  5. Bolha L, Ravnik-Glavac M, Glavac D. Long Noncoding RNAs as Biomarkers in Cancer. Dis Markers. 2017;2017:7243968.

    PubMed  PubMed Central  Google Scholar 

  6. Zhang Q, Zhong C, Duan S. The tumorigenic function of LINC00858 in cancer. Biomed Pharmacother. 2021;143:112235.

    PubMed  CAS  Google Scholar 

  7. Zhang Y, Zhu H, Sun N, et al. Linc00941 regulates esophageal squamous cell carcinoma via functioning as a competing endogenous RNA for miR-877-3p to modulate PMEPA1 expression. Aging (Albany NY). 2021;13:17830–46.

    PubMed  CAS  Google Scholar 

  8. Yan X, Zhang D, Wu W, et al. Mesenchymal Stem Cells Promote Hepatocarcinogenesis via lncRNA-MUF Interaction with ANXA2 and miR-34a. Cancer Res. 2017;77:6704–16.

    PubMed  CAS  Google Scholar 

  9. Morgenstern E, Kretz M. The human long non-coding RNA LINC00941 and its modes of action in health and disease. Biol Chem. 2023. https://doi.org/10.1515/hsz-2023-0183.

    Article  PubMed  Google Scholar 

  10. Kunej T, Obsteter J, Pogacar Z, Horvat S, Calin GA. The decalog of long non-coding RNA involvement in cancer diagnosis and monitoring. Crit Rev Clin Lab Sci. 2014;51:344–57.

    PubMed  CAS  Google Scholar 

  11. Wang J, He Z, Liu X, et al. LINC00941 promotes pancreatic cancer malignancy by interacting with ANXA2 and suppressing NEDD4L-mediated degradation of ANXA2. Cell Death Dis. 2022;13:718.

    PubMed  PubMed Central  CAS  Google Scholar 

  12. Li Z, Jin Q, Sun Y. LINC00941 promoted in vitro progression and glycolysis of laryngocarcinoma by upregulating PKM via activating the PI3K/AKT/mTOR signaling pathway. J Clin Lab Anal. 2022;36:e24406.

    PubMed  PubMed Central  CAS  Google Scholar 

  13. Shree B, Tripathi S, Sharma V. Transforming Growth Factor-Beta-Regulated LncRNA-MUF Promotes Invasion by Modulating the miR-34a Snail1 Axis in Glioblastoma Multiforme. Front Oncol. 2021;11:788755.

    PubMed  CAS  Google Scholar 

  14. Wu N, Jiang M, Liu H, et al. LINC00941 promotes CRC metastasis through preventing SMAD4 protein degradation and activating the TGF-beta/SMAD2/3 signaling pathway. Cell Death Differ. 2021;28:219–32.

    PubMed  CAS  Google Scholar 

  15. Liu J, Li Z, Zhang T, et al. Long Noncoding RNA LINC00941 Promotes Cell Proliferation and Invasion by Interacting with hnRNPK in Oral Squamous Cell Carcinoma. Nutr Cancer. 2022;74:2983–95.

    PubMed  CAS  Google Scholar 

  16. Wang J, He Z, Xu J, Chen P, Jiang J. Long noncoding RNA LINC00941 promotes pancreatic cancer progression by competitively binding miR-335-5p to regulate ROCK1-mediated LIMK1/Cofilin-1 signaling. Cell Death Dis. 2021;12:36.

    PubMed  PubMed Central  Google Scholar 

  17. Xu M, Cui R, Ye L, et al. LINC00941 promotes glycolysis in pancreatic cancer by modulating the Hippo pathway. Mol Ther Nucleic Acids. 2021;26:280–94.

    PubMed  PubMed Central  CAS  Google Scholar 

  18. Lu JT, Yan ZY, Xu TX, et al. Reciprocal regulation of LINC00941 and SOX2 promotes progression of esophageal squamous cell carcinoma. Cell Death Dis. 2023;14:72.

    PubMed  PubMed Central  CAS  Google Scholar 

  19. Luo C, Tao Y, Zhang Y, et al. Regulatory network analysis of high expressed long non-coding RNA LINC00941 in gastric cancer. Gene. 2018;662:103–9.

    PubMed  CAS  Google Scholar 

  20. Beeraka NM, Gu H, Xue N, et al. Testing lncRNAs signature as clinical stage-related prognostic markers in gastric cancer progression using TCGA database. Exp Biol Med (Maywood). 2022;247:658–71.

    PubMed  CAS  Google Scholar 

  21. Fang Y, Yang Y, Zhang X, et al. A Co-Expression Network Reveals the Potential Regulatory Mechanism of lncRNAs in Relapsed Hepatocellular Carcinoma. Front Oncol. 2021;11:745166.

    PubMed  PubMed Central  CAS  Google Scholar 

  22. Chang L, Zhou D, Luo S. Novel lncRNA LINC00941 Promotes Proliferation and Invasion of Colon Cancer Through Activation of MYC. Onco Targets Ther. 2021;14:1173–86.

    PubMed  PubMed Central  Google Scholar 

  23. Ren MH, Chen S, Wang LG, Rui WX, Li P. LINC00941 Promotes Progression of Non-Small Cell Lung Cancer by Sponging miR-877-3p to Regulate VEGFA Expression. Front Oncol. 2021;11:650037.

    PubMed  PubMed Central  CAS  Google Scholar 

  24. Fang L, Wang SH, Cui YG, Huang L. LINC00941 promotes proliferation and metastasis of pancreatic adenocarcinoma by competitively binding miR-873-3p and thus upregulates ATXN2. Eur Rev Med Pharmacol Sci. 2021;25:1861–8.

    PubMed  CAS  Google Scholar 

  25. Chan JJ, Tay Y. Noncoding RNA:RNA Regulatory Networks in Cancer. Int J Mol Sci. 2018;19:1310.

    PubMed  PubMed Central  Google Scholar 

  26. Tan YT, Lin JF, Li T, Li JJ, Xu RH, Ju HQ. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun (Lond). 2021;41:109–20.

    PubMed  Google Scholar 

  27. Lupianez DG, Kraft K, Heinrich V, et al. Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions. Cell. 2015;161:1012–25.

    PubMed  PubMed Central  CAS  Google Scholar 

  28. Debaugny RE, Skok JA. CTCF and CTCFL in cancer. Curr Opin Genet Dev. 2020;61:44–52.

    PubMed  PubMed Central  CAS  Google Scholar 

  29. Li Y, Haarhuis JHI, Sedeno Cacciatore A, et al. The structural basis for cohesin-CTCF-anchored loops. Nature. 2020;578:472–6.

    PubMed  PubMed Central  CAS  Google Scholar 

  30. Fang C, Wang Z, Han C, et al. Cancer-specific CTCF binding facilitates oncogenic transcriptional dysregulation. Genome Biol. 2020;21:247.

    PubMed  PubMed Central  CAS  Google Scholar 

  31. Lu J, Yu L, Xie N, Wu Y, Li B. METTL14 Facilitates the Metastasis of Pancreatic Carcinoma by Stabilizing LINC00941 in an m6A-IGF2BP2-Dependent Manner. J Cancer. 2023;14:1117–31.

    PubMed  PubMed Central  CAS  Google Scholar 

  32. Ulitsky I, Bartel DP. lincRNAs: genomics, evolution, and mechanisms. Cell. 2013;154:26–46.

    PubMed  PubMed Central  CAS  Google Scholar 

  33. Becnel LB, Ochsner SA, Darlington YF, et al. Discovering relationships between nuclear receptor signaling pathways, genes, and tissues in Transcriptomine. Sci Signal. 2017. https://doi.org/10.1126/scisignal.aah6275.

    Article  PubMed  Google Scholar 

  34. Zou Z, Ohta T, Miura F, Oki S. ChIP-Atlas 2021 update: a data-mining suite for exploring epigenomic landscapes by fully integrating ChIP-seq, ATAC-seq and Bisulfite-seq data. Nucleic Acids Res. 2022;50:W175–82.

    PubMed  PubMed Central  CAS  Google Scholar 

  35. Castro-Mondragon JA, Riudavets-Puig R, Rauluseviciute I, et al. JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2022;50:D165–73.

    PubMed  CAS  Google Scholar 

  36. Karreth FA, Pandolfi pp. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 2013;3:1113.

    PubMed  PubMed Central  CAS  Google Scholar 

  37. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi pp. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146:353–8.

    PubMed  PubMed Central  CAS  Google Scholar 

  38. Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36:5661–7.

    PubMed  PubMed Central  CAS  Google Scholar 

  39. Cheng SC, Quintin J, Cramer RA, et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345:1250684.

    PubMed  PubMed Central  Google Scholar 

  40. Sun Q, Chen X, Ma J, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A. 2011;108:4129–34.

    PubMed  PubMed Central  CAS  Google Scholar 

  41. Tian T, Li X, Zhang J. mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. Int J Mol Sci. 2019;20:755.

    PubMed  PubMed Central  CAS  Google Scholar 

  42. Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R. PAK signaling in oncogenesis. Oncogene. 2009;28:2545–55.

    PubMed  PubMed Central  CAS  Google Scholar 

  43. Dawson JC, Serrels A, Stupack DG, Schlaepfer DD, Frame MC. Targeting FAK in anticancer combination therapies. Nat Rev Cancer. 2021;21:313–24.

    PubMed  PubMed Central  CAS  Google Scholar 

  44. Katsuno M, Adachi H, Banno H, Suzuki K, Tanaka F, Sobue G. Transforming growth factor-beta signaling in motor neuron diseases. Curr Mol Med. 2011;11:48–56.

    PubMed  CAS  Google Scholar 

  45. Xie F, Ling L, van Dam H, Zhou F, Zhang L. TGF-beta signaling in cancer metastasis. Acta Biochim Biophys Sin (Shanghai). 2018;50:121–32.

    PubMed  CAS  Google Scholar 

  46. Akhurst RJ, Hata A. Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov. 2012;11:790–811.

    PubMed  PubMed Central  CAS  Google Scholar 

  47. Heldin CH, Moustakas A. Signaling Receptors for TGF-beta Family Members. Cold Spring Harb Perspect Biol. 2016;8:a022053.

    PubMed  PubMed Central  Google Scholar 

  48. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol. 2012;13:616–30.

    PubMed  PubMed Central  CAS  Google Scholar 

  49. Muralidhar S, Filia A, Nsengimana J, et al. Vitamin D-VDR Signaling Inhibits Wnt/beta-Catenin-Mediated Melanoma Progression and Promotes Antitumor Immunity. Cancer Res. 2019;79:5986–98.

    PubMed  CAS  Google Scholar 

  50. Yu F, Yu C, Li F, et al. Wnt/beta-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021;6:307.

    PubMed  PubMed Central  CAS  Google Scholar 

  51. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843–50.

    PubMed  CAS  Google Scholar 

  52. Lee MH, Kundu JK, Chae JI, Shim JH. Targeting ROCK/LIMK/cofilin signaling pathway in cancer. Arch Pharm Res. 2019;42:481–91.

    PubMed  CAS  Google Scholar 

  53. Lu G, Zhou Y, Zhang C, Zhang Y. Upregulation of LIMK1 Is Correlated With Poor Prognosis and Immune Infiltrates in Lung Adenocarcinoma. Front Genet. 2021;12:671585.

    PubMed  PubMed Central  CAS  Google Scholar 

  54. Ishaq M, Lin BR, Bosche M, et al. LIM kinase 1 - dependent cofilin 1 pathway and actin dynamics mediate nuclear retinoid receptor function in T lymphocytes. BMC Mol Biol. 2011;12:41.

    PubMed  PubMed Central  CAS  Google Scholar 

  55. Dey A, Varelas X, Guan KL. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 2020;19:480–94.

    PubMed  PubMed Central  CAS  Google Scholar 

  56. Ma S, Meng Z, Chen R, Guan KL. The Hippo Pathway: Biology and Pathophysiology. Annu Rev Biochem. 2019;88:577–604.

    PubMed  CAS  Google Scholar 

  57. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22:96–118.

    PubMed  CAS  Google Scholar 

  58. Liu L, Michowski W, Kolodziejczyk A, Sicinski P. The cell cycle in stem cell proliferation, pluripotency and differentiation. Nat Cell Biol. 2019;21:1060–7.

    PubMed  PubMed Central  CAS  Google Scholar 

  59. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495–516.

    PubMed  PubMed Central  CAS  Google Scholar 

  60. Xu X, Lai Y, Hua ZC. Apoptosis and apoptotic body: disease message and therapeutic target potentials. Biosci Rep. 2019;39:495.

    Google Scholar 

  61. Babaei G, Aziz SG, Jaghi NZZ. EMT, cancer stem cells and autophagy; The three main axes of metastasis. Biomed Pharmacother. 2021;133:110909.

    PubMed  CAS  Google Scholar 

  62. Lusby R, Dunne P, Tiwari VK. Tumour invasion and dissemination. Biochem Soc Trans. 2022;50:1245–57.

    PubMed  PubMed Central  CAS  Google Scholar 

  63. Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov. 2021;20:629–51.

    PubMed  PubMed Central  CAS  Google Scholar 

  64. Shao J, Zhang B, Kuai L, Li Q. Integrated analysis of hypoxia-associated lncRNA signature to predict prognosis and immune microenvironment of lung adenocarcinoma patients. Bioengineered. 2021;12:6186–200.

    PubMed  PubMed Central  CAS  Google Scholar 

  65. Chen H, Zhou C, Hu Z, et al. Construction of an algorithm based on oncosis-related LncRNAs comprising the molecular subtypes and a risk assessment model in lung adenocarcinoma. J Clin Lab Anal. 2022;36:e24461.

    PubMed  PubMed Central  CAS  Google Scholar 

  66. Gugnoni M, Manicardi V, Torricelli F, et al. Linc00941 Is a Novel Transforming Growth Factor beta Target That Primes Papillary Thyroid Cancer Metastatic Behavior by Regulating the Expression of Cadherin 6. Thyroid. 2021;31:247–63.

    PubMed  CAS  Google Scholar 

  67. Zou Z, Ma T, He X, et al. Long intergenic non-coding RNA 00324 promotes gastric cancer cell proliferation via binding with HuR and stabilizing FAM83B expression. Cell Death Dis. 2018;9:717.

    PubMed  PubMed Central  Google Scholar 

  68. Wang S, Cheng Y, Yang P, Qin G. Silencing of Long Noncoding RNA LINC00324 Interacts with MicroRNA-3200-5p to Attenuate the Tumorigenesis of Gastric Cancer via Regulating BCAT1. Gastroenterol Res Pract. 2020;2020:4159298.

    PubMed  PubMed Central  Google Scholar 

  69. Liu H, Wu N, Zhang Z, et al. Long Non-coding RNA LINC00941 as a Potential Biomarker Promotes the Proliferation and Metastasis of Gastric Cancer. Front Genet. 2019;10:5.

    PubMed  PubMed Central  Google Scholar 

  70. Hartung M, Anastasi E, Mamdouh ZM, et al. Cancer driver drug interaction explorer. Nucleic Acids Res. 2022;50:W138–44.

    PubMed  PubMed Central  CAS  Google Scholar 

  71. Wang Y, Zhao D, Wang H, et al. Long non-coding RNA-LINC00941 promotes the proliferation and invasiveness of glioma cells. Neurosci Lett. 2023;795:136964.

    PubMed  CAS  Google Scholar 

  72. Pan H, Wei W, Fu G, Pan J, Jin B. LINC00941 Promotes Cell Malignant Behavior and Is One of Five Costimulatory Molecule-Related lncRNAs That Predict Prognosis in Renal Clear Cell Carcinoma. Medicina (Kaunas). 2023;59:187.

    PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank PubMed for the valuable information. Figs. 2 and 4 were created by BioRender (biorender.com).

Funding

This study was supported by the Qiantang Scholars Fund in Hangzhou City University (No. 210000–581835).

Author information

Author notes

  1. Qibin Yan and Xinming Su are co-first authors of this work.

Authors and Affiliations

  1. Institute of Pharmacy, Zhejiang University of Technology, Hangzhou, Zhejiang, China

    Qibin Yan, Qing Xia & Hanbing Li

  2. Department of Clinical Medicine, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China

    Qibin Yan, Xinming Su, Yunzhu Chen, Zehua Wang, Qing Xia, Jiahua Si & Shiwei Duan

  3. Department of Pharmacy, Hangzhou City University School of Medicine, Hangzhou, Zhejiang, China

    Qibin Yan, Wenbo Han & Yunan Mao

  4. Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China

    Xinming Su, Yunzhu Chen, Zehua Wang, Wenbo Han, Qing Xia, Jiahua Si & Shiwei Duan

Authors
  1. Qibin Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinming Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yunzhu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zehua Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wenbo Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qing Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yunan Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jiahua Si
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hanbing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shiwei Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

QY, XS, YC, ZW, WH, QX, and YM collected and analyzed the literature, drafted the figures, and wrote the manuscript. SD and HL conceived the idea and gave the final approval of the submitted version. All authors have read and agreed to the published version of the manuscript.

Corresponding authors

Correspondence to Hanbing Li or Shiwei Duan.

Ethics declarations

Conflict of interest

All authors declare no competing interests.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 349 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yan, Q., Su, X., Chen, Y. et al. LINC00941: a novel player involved in the progression of human cancers. Human Cell 37, 167–180 (2024). https://doi.org/10.1007/s13577-023-01002-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-023-01002-5

Keywords

Search

Navigation